selected scholarly activity
-
chapters
- Prevention of Stroke in Atrial Fibrillation. 1092-1100. 2018
- Prevention of Stroke in Patients With Atrial Fibrillation. 1129-1137. 2014
- Periprocedural and Long‐Term Anticoagulation. 77-84. 2011
- Atrial Fibrillation: Antithrombotic Therapy. 581-595. 2009
- Anticoagulation Issues. 41-50. 2007
- Clinical Trials of Pacing Modes. 337-356. 2007
- Clinical trials of pacing modes. 337-356. 2006
-
conferences
- ANDEXANET ALFA VS NON-SPECIFIC TREATMENTS FOR INTRACEREBRAL HEMORRHAGE IN PATIENTS TAKING FACTOR XA INHIBITORS - INDIVIDUAL PATIENT DATA ANALYSIS OF ANNEXA-4 AND TICH-NOAC. International Journal of Stroke. 450-450. 2023
- Semi-Markov Offline Reinforcement Learning for Healthcare. Proceedings of Machine Learning Research. 119-137. 2022
- Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. Canadian Journal of Cardiology. 389-395. 2019
- Characterization of Patients With Embolic Strokes of Uncertain Source in the Navigate-ESUS Trial. Stroke. 2018
- EFFECTIVENESS OF IMPLEMENTATION INTERVENTIONS IN IMPROVING PHYSICIAN ADHERENCE TO GUIDELINE RECOMMENDATIONS IN HEART FAILURE: A SYSTEMATIC REVIEW. BMJ Open. 288-288. 2017
- Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patients With Cardiovascular Risk Factors: ASSERT II. Circulation. E714-E714. 2016
- Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa. Blood. 143-143. 2016
- Comparison of Contemporary Bleeding Risk Scores in Patients With Non-Valvular Atrial Fibrillation Treated With Dabigatran or Warfarin: Insights From the RE-LY Trial. Circulation. 2016
- The Impact of Dual Antiplatelet Therapy on Mortality: A Patient-Level Meta-Analysis. Circulation. 2016
- Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation: experiences from the RELY trial. Journal of the American Heart Association. 47-47. 2016
- Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation: insights from the RE-LY trial. European Heart Journal. 429-429. 2016
- Surgical ablation of atrial fibrillation ablation in 11 countries: the LAAOS III trial. European Heart Journal. 280-280. 2016
- Andexanet Alfa, a Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers.. Stroke. 2016
- ANNEXA (TM)-R Part 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Sustained Reversal of Rivaroxaban-Induced Anticoagulation in Older Subjects by Andexanet Alfa (PRT064445), a Universal Antidote for Factor XA (FXA) Inhibitors. Circulation. 2274-2274. 2015
- Efficacy and Safety of Dabigatran Compared With Warfarin in Patients With Atrial Fibrillation and Normal Renal Function Over Time: Insights From the RE-LY Trial. Circulation. 2015
- Sub-clinical Atrial Fibrillation in Elderly Primary Care Patients Without Clinical Atrial Fibrillation. Circulation. 2015
- NAVIGATE ESUS: Multicenter, Randomized, Double-Blind, Phase III Trial of Rivaroxaban vs. Aspirin for the Prevention of Recurrent Stroke and Systemic Embolism in Patients with Recent Embolic Stroke of Undetermined Source. Cerebrovascular Diseases. 34-35. 2015
- NAVIGATE ESUS: Phase-III RCT assessing prevention of stroke and systemic embolism in patients with embolic stroke of undetermined source. Journal of the Neurological Sciences. e364-e365. 2015
- NAVIGATE ESUS: Multicenter, randomized, double-blind, phase III study of prevention of recurrent stroke and systemic embolism in patients with recent embolic stroke of undetermined source. International Journal of Stroke. 36-37. 2015
- Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial. European Heart Journal. 862-862. 2015
- Real world usage of direct oral anticoagulants in patients undergoing electrical cardioversion for atrial tachyarrhythmias. European Heart Journal. 391-391. 2015
- Troponin T or I levels following ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. European Heart Journal. 208-208. 2015
- Navigate ESUS: Multicenter, randomized, double-blind, phase III study of prevention of recurrent stroke and systemic embolism in patients with recent embolic stroke of undetermined source. International Journal of Stroke. 431-432. 2015
- Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. Stroke. E280-E281. 2014
- Can Biomarkers Improve Risk Stratification of Atrial Fibrillation Patients? Analysis of 3578 Aspirin-treated Patients in ACTIVE and AVERROES. Circulation. 2014
- Pattern of Atrial Fibrillation and the Risk of Ischemic Stroke - A Systematic Review and Meta-Analysis. Circulation. 2014
- Risk of ischemic stroke or systemic embolism in aspirin-treated patients according to clinical presentation of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE or AVERROES. European Heart Journal. 726-726. 2014
- Statin use reduces incidence of adverse events in patients with atrial fibrillation in the ACTIVE-W, ACTIVE-A and AVERROES studies. European Heart Journal. 777-777. 2014
- The use of dabigatran according to body mass index: the RE-LY experience. European Heart Journal. 1111-1111. 2014
- Statin use reduces incidence of adverse events in patients with atrial fibrillation: analysis in ACTIVE-W & A and AVERROES studies. Journal of Thrombosis and Haemostasis. 7-8. 2014
- Apixaban Versus Aspirin in Atrial Fibrillation Patients >= 75 Years Old: an Analysis From the AVERROES Trial. Stroke. E187-E187. 2013
- Does the Degree of Left Ventricular Dysfunction or Symptom Status Influence the Risk of Stroke or Systemic Embolism Among Patients With Atrial Fibrillation and Heart Failure?-Results From the ACTIVE Study. Circulation. 2013
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis. Circulation. 2013
- Extracranial Systemic Embolic Events in Patients With Atrial Fibrillation: Incidence and Outcomes. Circulation. 2013
- RE-LY and RELY-ABLE: Long-term Follow-up of Patients With Non-valvular Atrial Fibrillation Receiving Dabigatran Etexilate for Up to 6.7 Years. Circulation. 2013
- Current Use of Oral Anticoagulants Therapy in Pacemaker Patients With Pacemaker-Detected Atrial Fibrillation: Results From a Four-Nation Physician Survey. Canadian Journal of Cardiology. S191-S191. 2013
- IMPACT OF ADDITIONAL LEFT ATRIAL LINES ON AF RECURRENCE IN PATIENTS UNDERGOING PULMONARY VEIN ISOLATION REDO PROCEDURE. Canadian Journal of Cardiology. S181-S181. 2013
- PULMONARY VEIN DIAMETER AND POST RADIOFREQUENCY ABLATION ATRIAL FIBRILLATION RECURRENCE: DOES SIZE MATTER?. Canadian Journal of Cardiology. S181-S181. 2013
- Predictors of Pacemaker Dependency and Heart Failure Hospitalizations in Pacemaker Patients in the Assert Trial. Canadian Journal of Cardiology. S358-S359. 2013
- Surgical Checklist to Reduce Pacemaker and Implantable Cardioverter-Defibrillator Lead Dislodgements. Canadian Journal of Cardiology. S360-S360. 2013
- Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the Rely-Able Double-Blind Randomized Trial. Circulation. 2793-2793. 2012
- Balancing the Benefits and Risks of Two Doses of Dabigatran Compared with Warfarin in Atrial Fibrillation. Circulation. 2012
- Cluster Randomized Controlled Trial to Test The Effect of a Multifaceted Comprehensive Cardiovascular Care Intervention on Clinical Outcomes in Atrial Fibrillation Patients Receiving Dabigatran. Circulation. 2012
- Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation - A RELY Substudy. Circulation. 2012
- Incidence of Pacemaker-Detected Atrial Tachyarrhythmias in Elderly Patients with Hypertension and a History of Stroke or Transient Ischemic Attack. Circulation. 2012
- 066 Active Versus Passive Fixation Atrial Leads: Incidence of Atrial Tachyarrhythmias Among Patients of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). Canadian Journal of Cardiology. S110-S111. 2012
- 768 Prevalence and Predictors of Sub-Clinical Atrial Fibrillation in Pacemaker Patients. Canadian Journal of Cardiology. S394-S394. 2012
- 902 Cluster Randomized Controlled Trial to Test the Effect of Computer-Generated Individualized Audit and Feedback to Patients and Physicians on Clinical Outcomes in Atrial Fibrillation Patients Participating in a Large Multi-Center Trial of Dabigatran. Canadian Journal of Cardiology. S417-S417. 2012
- Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis. European Heart Journal. 52-52. 2012
- Prognostic value of electrocardiographic left ventricular hypertrophy in patients with atrial fibrillation. European Heart Journal. 376-376. 2012
- Efficacy and Safety of Dabigatran Versus Warfarin in Patients with Atrial Fibrillation: Analysis in Asian Population in RE-LY Trial. Cerebrovascular Diseases. 9-9. 2012
- Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE). Circulation. 2368-2369. 2011
- Global Variation in the Etiology and Management of Atrial Fibrillation: Results from a Global Atrial Fibrillation Registry. Circulation. 2011
- The Results of the PALLAS Study. Circulation. 2369-2369. 2011
- 504 Does cardiac resynchronization therapy improve outcomes in patients with chronic atrial tachyarrhythmias? results from the resynchronization for ambulatory heart failure trial (raft). Canadian Journal of Cardiology. S245-S245. 2011
- 901 Does cardiac resynchronization therapy improve outcomes in patients with chronic atrial tachyarrhythmias? Results from the resynchronization for ambulatory heart failure trial (RAFT). Canadian Journal of Cardiology. S334-S335. 2011
- Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial. European Heart Journal. 671-671. 2011
- Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial. European Heart Journal. 6-6. 2011
- Dabigatran and warfarin affects the coagulation process at different levels during long-term treatment - a RELY substudy. European Heart Journal. 467-467. 2011
- Differences in baseline electrophysiologic properties and electrical remodeling among pacemaker patients who develop atrial tachyarrhythmias: results of the ASSERT mechanisms of atrial fibrillation St. European Heart Journal. 930-930. 2011
- Effect of dronedarone in patients with permanent atrial fibrillation during the ATHENA study. European Heart Journal. 618-618. 2011
- Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial. European Heart Journal. 465-465. 2011
- Efficacy and safety of the novel oral factor Xa inhibitor apixaban in atrial fibrillation (AF) patients with chronic kidney disease (CKD): the AVERROES trial. European Heart Journal. 6-6. 2011
- Importance of algorithm-based warfarin dosing in the quality of anticoagulation control in atrial fibrillation - a multilevel analysis. European Heart Journal. 461-461. 2011
- No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the rely trial. Journal of Thrombosis and Haemostasis. 346-346. 2011
- Randomized comparison of the DAWN AC computer program and a simple manual nomogram for quality of warfarin dosing. Journal of Thrombosis and Haemostasis. 302-302. 2011
- Vitamin K antagonist dosing methods and individual patient quality of INR control in the international active W anticoagulation study. Journal of Thrombosis and Haemostasis. 445-446. 2011
- INTERLEUKIN-6 AND C-REACTIVE PROTEIN AND RISK FOR DEATH AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION. Journal of the American College of Cardiology. E91-E91. 2011
- AVERROES: Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Strokes. Stroke. E81-E81. 2011
- Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial. American Journal of Respiratory and Critical Care Medicine. 671-671. 2011
- D-dimer is Prognostic for Stroke, Major Bleeding and Death During Anticoagulation of Atrial Fibrillation - a RELY Substudy. Circulation. 2010
- NT-proBNP is Prognostic for Stroke and Death in Atrial Fibrillation - a RELY Substudy. Circulation. 2010
- The Relationship Between Atrial High-Rate Episodes and Stroke: The Asymptomatic Stroke and Atrial Fibrillation Evaluation in Pacemaker Patients (ASSERT) Trial. Circulation. 2220-2221. 2010
- European Society of Cardiology: Apixaban or aspirin in decreasing stroke risk (The AVERROES Trial). P and T. 580-581. 2010
- RISK OF COMPLICATIONS AMONG ELDERLY RECIPIENTS OF PERMANENT PACEMAKERS. Canadian Journal of Cardiology. 90D-90D. 2010
- Differences in baseline characteristics and in effects of dronedarone on outcomes in patients with atrial fibrillation across regions: post-hoc analysis from the Athena study. European Heart Journal. 717-717. 2010
- Effects of dronedarone on clinical outcomes in 432 patients with lone atrial fibrillation: pooled post-hoc analysis from the Athena/Euridis/Adonis studies. European Heart Journal. 716-716. 2010
- Effects of the oral factor Xa inhibitor Betrixaban on pharmacodynamic markers in EXPLORE-Xa, a phase II atrial fibrillation study. European Heart Journal. 107-107. 2010
- Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation. European Heart Journal. 886-886. 2010
- Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: the RE-LY study. Journal of Neurology. S31-S31. 2010
- DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION - AN ANALYSIS OF PATIENTS UNDERGOING CARDIOVERSION. Journal of the American College of Cardiology. 2010
- EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY. Journal of the American College of Cardiology. 2010
- IMPACT OF DRONEDARONE STARTED RAPIDLY AFTER AMIODARONE DISCONTINUATION. Journal of the American College of Cardiology. 2010
- Reduced Cerebral Bleeding Rates with Dabigatran Compared to Warfarin in Patients with Atrial Fibrillation: Results of RE-LY. Neurology. A281-A281. 2010
- Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE‐I, European CRT survey, German pre‐SCD II registry, and MADIT‐CRT. European Journal of Heart Failure. 1214-1219. 2009
- Impact of the Modified Henry Ford Warfarin Maintenance Dosing Algorithm an Quality of Anticoagulation at a Specialist Anticoagulation Clinic. Circulation. S1150-S1150. 2009
- Effects of dronedarone on clinical outcomes in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA study. European Heart Journal. 450-450. 2009
- Impact of dronedarone on hospitalization for atrial fibrillation: insights from ATHENA. European Heart Journal. 450-450. 2009
- Lead dislodgement and lead related cardiac perforation in ICD patients. European Heart Journal. 309-309. 2009
- Management of atrial fibrillation in the emergency department: are we adhering to guidelines?. European Heart Journal. 819-819. 2009
- Wide area circumferential ablation for pulmonary vein isolation in patients with atrial fibrillation and pulmonary vein stenosis. European Heart Journal. 414-414. 2009
- Effect of Dronedarone on Cardiovascular Outcomes: A Meta-analysis of Five Randomized Controlled Trials in 6157 Patients With Atrial Fibrillation/Flutter. Journal of the American College of Cardiology. A113-A114. 2009
- Underuse of Evidence Based Methods for Management of Warfarin in Atrial Fibrillation Patients in Hamilton, Canada. Journal of the American College of Cardiology. A368-A368. 2009
- European Society of Cardiology, 2009 Congress and A Comparison of two Asthma Medications: The RELY trial (warfarin and dabigatran). P and T. 565. 2009
- Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. Blood. 18-18. 2008
- Rhythm- and Rate-Controlling Effects of Dronedarone in Patients with Atrial Fibrillation: Insights From the ATHENA Trial. Circulation. S827-S827. 2008
- Addition of dual anti-platelet therapy to oral anticoagulation, in patients with atrial fibrillation, does not increase risk of major hemorrhage: analysis from the ACTIVE W study. European Heart Journal. 745-746. 2008
- Cognitive function and anticoagulation control in patients with atrial fibrillation. European Heart Journal. 258-258. 2008
- Placebo-controlled double-blind dose-ranging study of the efficacy and safety of celivarone for the prevention of ventricular arrhythmia-triggered ICD interventions. Journal of the American College of Cardiology. A2-A2. 2008
- The atrial fibrillation and congestive heart failure (AF-CHF) trial. Circulation. 2631-2631. 2007
- Lone atrial fibrillation: Long-term clinical and echocardiographic follow-up from the Canadian registry of atrial fibrillation. Circulation. 366-367. 2007
- A systematic review of randomized trials comparing catheter-based radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. Canadian Journal of Cardiology. 148C-148C. 2007
- Device-related infections among patients with pacemakers and implantable defibrillators: Incidence, risk factors and consequences. Canadian Journal of Cardiology. 174C-175C. 2007
- Does left atrial size remodelling predict recurrence of atrial fibrillation after circumferential pulmonary vein isolation?. Journal of Cardiovascular Electrophysiology. S80-S81. 2007
- Effects of forced ventricular pacing in patients undergoing atrioventricular node ablation for ventricular rate control in patients with atrial fibrillation. Canadian Journal of Cardiology. 64C-64C. 2007
- Aspirin and the Risk of Heart Failure Hospitalization in Patients with Atrial Fibrillation and a Prior History of Heart Failure: An ACTIVE-W Analysis. Journal of Cardiac Failure. 762-762. 2006
- Does left atrial scarring determine success in patients undergoing pulmonary vein isolation for atrial fibrillation?. European Heart Journal. 42-42. 2006
- Dronedarone: rhythm and rate control in management of atrial fibrillation. Focus on symptomatic arrhythmia. European Heart Journal. 33-33. 2006
- Incidence of stroke in paroxysmal versus persistent/permanent atrial fibrillation and effects of oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. European Heart Journal. 446-446. 2006
- Will implementing a syncope assessment algorithm at emergency room reduce hospital admissions and health care costs?. European Heart Journal. 378-378. 2006
- The management of hypertension in patients with atrial fibrillation: Impact of specialist care. Ethnicity and Disease. S47-S47. 2006
- 2004 Canadian Cardiovascular Society Consensus Conference: Atrial Fibrillation.. Canadian Journal of Cardiology. 9B-73B. 2005
- Competing risks for arrhythmic versus nonarrhythmic death in prophylactic ICD therapy early after myocardial infarction. Circulation. 502-502. 2004
- Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. Circulation. 461-461. 2004
- The EURIDIS and ADONIS trials: Dronedarone for maintaining sinus rhythm in patients with atrial fibrillation/flutter. Circulation. 741-741. 2004
- Journal of Cardiovascular Electrophysiology: Introduction. Journal of Cardiovascular Electrophysiology. 2003
- Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. American Journal of Cardiology. 9-14. 2003
- Azimilide reduces symptom burden at the time of arrhythmia recurrence in patients with atrial fibrillation. Journal of the American College of Cardiology. 82A-82A. 2002
- Left atrial dimension is associated with atrial fibrillation recurrence: Four-year echo follow-up data. Journal of the American College of Cardiology. 80A-80A. 2002
- Prevention of post-cardiac surgery atrial fibrillation is not associated with decrease in post-operative stroke: Meta-analysis. Journal of the American College of Cardiology. 85A-85A. 2002
- Metoprolol prophylaxis against post-operative atrial fibrillation increases length of hospital stay in patients not on pre-operative beta-blockers: The beta-blocker length of stay (BLOS) trial. Circulation. 773-773. 2001
- Prevention of atrial fibrillation after cardiac surgery: A meta-analysis. Circulation. 773-773. 2001
- The effect of clinical risk stratification on the cost-effectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study. Circulation. 345-345. 2001
- Use of antiarrhythmic drugs for atrial fibrillation (AF) despite the presence of precautionary clinical conditions.. Circulation. 774-774. 2001
- Asymptomatic atrial fibrillation and flutter are common among patients with symptomatic arrhythmias: Lessons from the azimilide supraventricular arrhythmia program (ASAP) trials. Circulation. 673-673. 2000
- Dose response relationships of azimilide for control of atrial fibrillation/flutter: Meta-analysis of four randomized trials. Circulation. 673-673. 2000
- Two populations of syncope patients with negative tilt tests. Circulation. 370-370. 2000
- New onset atrial fibrillation: Gender differences in presentation, outcome, and treatment. Journal of the American College of Cardiology. 132A-132A. 2000
- Effect of pacemaker dependency on the benefit of physiologic over ventricular pacing. Circulation. 643-643. 1999
- New onset atrial fibrillation: Anticoagulant use in The Canadian Registry of Atrial Fibrillation (CARAF). Circulation. 500-500. 1999
- Recurrence of atrial fibrillation following its initial diagnosis: Follow-up of the Canadian Registry of Atrial Fibrillation. Circulation. 286-286. 1999
- The effect of pacemaker selection on functional capacity in the Canadian Trial of Physiologic Pacing (CTOPP). Circulation. 465-465. 1999
- Prophylactic antiarrhythmic therapy for the prevention of sudden death in high-risk patients: drugs and devices. European Heart Journal, Supplement. C31-C35. 1999
- Anamnestic diagnostic criteria for syncope due to ventricular tachycardia.. Circulation. 846-846. 1998
- Causes of sudden death in patients with implantable cardioverter defibrillators: Insights from the Canadian Implantable Defibrillator Study. Circulation. 165-165. 1998
- Circadian variation of paroxysmal atrial fibrillation: Influence of atrial pacing. Circulation. 510-510. 1998
- Quality of life improves with defibrillator therapy but not with amiodarone: Results from the Canadian Implantable Defibrillator Study. Circulation. 13-13. 1998
- Synergy between amiodarone and beta-blockers after myocardial infarction. Circulation. 93-93. 1998
- XIX congress of the European Society of Cardiology August 24-28, 1997, Stockholm, Sweden.. Giornale Italiano di Cardiologia. 1197-1200. 1997
- A randomized, double-blind, placebo-controlled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial fibrillation/flutter. Circulation. 2536-2536. 1997
- Lone atrial fibrillation from a prospective multicenter study: Clinical outcome and comparison to atrial fibrillation with cardiovascular disease. Circulation. 414-414. 1997
- Amiodarone side effects and laboratory abnormalities - Reliable rates from a large double-blind trial.. Circulation. 1435-1435. 1996
- Is atrial fibrillation pattern a risk factor for thromboembolism in nonrheumatic atrial fibrillation?. Circulation. 3891-3891. 1996
- Which patients surviving acute myocardial infarction are most likely to benefit from amiodarone?. Circulation. 1437-1437. 1996
- Which patients surviving acute myocardial infarction are most likely to benefit from amiodarone?. Circulation. 1438-1438. 1996
- Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. European Heart Journal. 48-51. 1996
- TREATMENT OF SYMPTOMATIC SUPRAVENTRICULAR ARRHYTHMIAS WITH BIDISOMIDE. Circulation. 3721-3721. 1995
- COMPARISON OF ONE-YEAR MORTALITY OF ACUTE MYOCARDIAL-INFARCTION BETWEEN 1980, 1987, AND 1992 IN A GEOGRAPHICALLY-DEFINED STABLE-POPULATION. Circulation. 603-603. 1994
- DEFINITION OF PREDICTED EFFECTIVE THERAPY FOR VT/VF BY PROGRAMMED STIMULATION - RANDOMIZED COMPARISON OF PATIENT RESPONSE CRITERIA. Circulation. 339-339. 1994
- How to evaluate antiarrhythmic agents in an essentially asymptomatic population.. Canadian Journal of Cardiology. 330. 1994
- COMPARISON OF MORTALITY FROM ACUTE MYOCARDIAL-INFARCTION BETWEEN 1980, 1987, AND 1992 IN A GEOGRAPHICALLY-DEFINED STABLE-POPULATION. Circulation. 508-508. 1993
- CANADIAN AMIODARONE MYOCARDIAL-INFARCTION ARRHYTHMIA TRIAL (CAMIAT) PILOT RESULTS. Circulation. 139-139. 1990
- CANADIAN ATRIAL-FIBRILLATION ANTICOAGULATION (CAFA) STUDY. Circulation. 108-108. 1990
- ·P-27 Systems of logging exclusions in multicenter clinical trials. Contemporary Clinical Trials. 288-288. 1990
- COMPARISON OF THE 1 AND 6 HOUR HOLTERS TO THE 24 HOUR HOLTER IN SURVIVORS OF MYOCARDIAL-INFARCTION. Circulation. 394-394. 1987
- PREVALENCE OF LATE VENTRICULAR ARRHYTHMIA POSTMYOCARDIAL INFARCTION IN A DEFINED COMMUNITY. Circulation. 394-394. 1987
- AMIODARONE PHARMACODYNAMICS DURING THERAPY INITIATION. Circulation. 168-168. 1985
- THE EFFECT OF INTRAVENOUS PROPAFENONE ON RAPID ATRIAL-FIBRILLATION. Circulation. 253-253. 1985
- AMIODARONE AND N-DESETHYLAMIODARONE PLASMA AND MYOCARDIAL DISPOSITION KINETICS FOLLOWING ACUTE AND CHRONIC ADMINISTRATION. Clinical Pharmacology and Therapeutics. 257-257. 1983
- EFFICACY AND ELECTROPHYSIOLOGY OF IMIPRAMINE IN PATIENTS WITH VENTRICULAR-TACHYCARDIA. Journal of the American College of Cardiology. 671-671. 1983
- OBJECTIVE AND SUBJECTIVE ASSESSMENT OF EFFECTS OF LORCAINIDE ON SLEEP. Circulation. 360-360. 1983
- CLINICAL-PHARMACOLOGY OF PROPAFENONE. Circulation. 68-68. 1982
-
journal articles
- The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. Circulation. 149:1315-1318. 2024
- Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials. Circulation. Cardiovascular Quality and Outcomes. 17:e010269. 2024
- Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation. 149:981-988. 2024
- Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. Circulation. 149:932-943. 2024
- Optimizing warfarin dosing for patients with atrial fibrillation using machine learning. Scientific Reports. 14:4516. 2024
- Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials. Journal of the American College of Cardiology. 83:669-678. 2024
- Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes. Stroke. 55:392-402. 2024
- Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. New England Journal of Medicine. 390:107-117. 2024
- Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial. Circulation: Arrhythmia and Electrophysiology. 17:e01238. 2024
- The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. 24:117-127. 2024
- Cerebral microbleeds and asundexian in non-cardioembolic ischemic stroke: Secondary analyses of the PACIFIC-STROKE randomized trial. International Journal of Stroke. 17474930231216339. 2023
- Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurology. 22:1140-1149. 2023
- Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care. Journal of the American Medical Association (JAMA). 330:1872-1872. 2023
- Small-volume tubes to reduce anemia and transfusion (STRATUS): a pilot study. Canadian Journal of Anaesthesia. 70:1797-1806. 2023
- Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III. Circulation. 148:1298-1304. 2023
- Atrial Fibrillation Recurrence in Patients With Transient New-Onset Atrial Fibrillation Detected During Hospitalization for Noncardiac Surgery or Medical Illness. ACP journal club. 176:1299-1307. 2023
- The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes. 9:502-510. 2023
- Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC‐AF risk scores. American Heart Journal. 261:55-63. 2023
- GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clinical Research in Cardiology. 112:759-771. 2023
- Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal. 44:1807-1814. 2023
- Cost Implications of Left Atrial Appendage Occlusion During Cardiac Surgery: A Cost Analysis of the LAAOS III Trial. Journal of the American Heart Association. 12:e028716. 2023
- Association of the Timing and Extent of Cardiac Implantable Electronic Device Infections With Mortality. JAMA cardiology. 8:484-484. 2023
- The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. Atherosclerosis. 372:41-47. 2023
- Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 147:1026-1038. 2023
- Response to the Letter by Spurling and Colleagues. Critical Care. 27:65. 2023
- Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. European Heart Journal. 44:208-218. 2023
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:786-795. 2022
- Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations. ACP journal club. 175:1658-1665. 2022
- Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. New England Journal of Medicine. 387:2100-2101. 2022
- Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. European Heart Journal. 43:3542-3552. 2022
- Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:648-659. 2022
- Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. New England Journal of Medicine. 387:978-988. 2022
- Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. Canadian Journal of Cardiology. 38:1434-1441. 2022
- Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. 400:997-1007. 2022
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:462-473. 2022
- Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF. Open Heart. 9:e002038-e002038. 2022
- Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. Europace. 24:1058-1064. 2022
- Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardioscience. 118:2112-2123. 2022
- Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation. 145:1875-1877. 2022
- Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Critical Care. 26:180. 2022
- Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thrombosis and Haemostasis. 122:998-1005. 2022
- Prediction of disability-free survival in healthy older people. GeroScience. 44:1641-1655. 2022
- Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. 399:1383-1390. 2022
- Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding. Journal of the American College of Emergency Physicians Open. 3:e12655. 2022
- Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. Circulation. 145:392-409. 2022
- Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial. Heart Rhythm O2. 3:40-49. 2022
- Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. Stroke. 53:532-543. 2022
- Prospective long-term follow-up of silicone-polyurethane–insulated implantable cardioverter-defibrillator leads. Heart Rhythm O2. 3:57-64. 2022
- Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 145:242-255. 2022
- Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardioscience. 118:295-304. 2022
- Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke. 53:45-52. 2022
- Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. CJC OPEN. 3:1482-1489. 2021
- Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). Open Forum Infectious Diseases. 8:ofab513. 2021
- Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. Circulation. Heart Failure. 14:e008548. 2021
- Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. The BMJ. 375:e066450-e066450. 2021
- LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry. Journal of the American Heart Association. 10:e017735. 2021
- Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. New England Journal of Medicine. 385:1053-1055. 2021
- Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circulation: Arrhythmia and Electrophysiology. 14:e009591. 2021
- Derivation and validation of a two‐variable index to predict 30‐day outcomes following heart failure hospitalization. ESC heart failure. 8:2690-2697. 2021
- Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis. 121:1097-1106. 2021
- Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart. 107:1130-1137. 2021
- Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology. 78:14-23. 2021
- Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. New England Journal of Medicine. 384:2081-2091. 2021
- Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). American Journal of Cardiology. 149:27-35. 2021
- Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke. 52:2096-2105. 2021
- Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 77:2875-2886. 2021
- Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals. Cardioscience. 117:1523-1531. 2021
- Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. Circulation. 143:1863-1873. 2021
- Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Canadian Journal of Cardiology. 37:803-809. 2021
- Screening for Atrial Fibrillation in the Older Population. JAMA cardiology. 6:558-558. 2021
- Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. Thrombosis and Haemostasis. 121:518-528. 2021
- Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. American Heart Journal. 233:48-58. 2021
- Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 77:1197-1207. 2021
- Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardioscience. 117:942-949. 2021
- Semi-automatic measurement of intracranial hemorrhage growth on non-contrast CT. International Journal of Stroke. 16:192-199. 2021
- High-Sensitivity Estimate of the Incidence of New-Onset Atrial Fibrillation in Critically Ill Patients. Critical Care Explorations. 3:e0311-e0311. 2021
- Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. JAMA Neurology. 78:11-11. 2021
- Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Journal of the American Heart Association. 9:e018984. 2020
-
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the
ATHENA study. Clinical Cardiology. 43:1469-1477. 2020 - Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials. Trauma Surgery and Acute Care Open. 5:e000605-e000605. 2020
- Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. Circulation. 142:1697-1699. 2020
- Permanent Bilateral Carotid Filters for Stroke Prevention in Atrial Fibrillation. Current Cardiology Reports. 22:144. 2020
- Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. JAMA Neurology. 77:1233-1233. 2020
- Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke. 51:2901-2909. 2020
- Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 13:e008655. 2020
- Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial. CJC OPEN. 2:354-359. 2020
- Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials. Journal of Thrombosis and Haemostasis. 18:2287-2295. 2020
- Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?. American Heart Journal. 226:152-160. 2020
- Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. Journal of Stroke and Cerebrovascular Diseases. 29:104936-104936. 2020
- Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. Stroke. 51:2139-2147. 2020
- Restricted versus liberal intraoperative benzodiazepine use in cardiac anaesthesia for reducing delirium (B-Free Pilot): a pilot, multicentre, randomised, cluster crossover trial. British Journal of Anaesthesia. 125:38-46. 2020
- The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. American Heart Journal. 225:69-77. 2020
- Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation. 141:1841-1854. 2020
- Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. Europace. 22:870-877. 2020
- Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. Stroke. 51:1797-1804. 2020
- Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. 141:1141-1151. 2020
- Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. Stroke. 51:938-943. 2020
- Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology (EJPC). 27:296-307. 2020
- Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trial. American Heart Journal. 220:116-126. 2020
- Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. JAMA Neurology. 77:43-43. 2020
- Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. PLoS ONE. 15:e0226259-e0226259. 2020
- Correction to: Prevention of Infections in Cardiac Surgery study (PICS): study protocol for a pragmatic cluster-randomized factorial crossover pilot trial. Trials. 20:595. 2019
- Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. Journal of the American College of Cardiology. 74:2845-2854. 2019
- Andexanet Response. Annals of Emergency Medicine. 74:724-725. 2019
- Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. Stroke. 50:3184-3190. 2019
- Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 140:1451-1459. 2019
- Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. European Heart Journal. 40:3026-3032. 2019
- Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke. 50:2477-2485. 2019
- Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology. 74:1519-1528. 2019
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 157:682-691.e2. 2019
- Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 140:529-537. 2019
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 157:403-412.e5. 2019
- Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Journal of Stroke and Cerebrovascular Diseases. 28:2273-2279. 2019
- Andexanet Alfa for Bleeding with Factor Xa Inhibitors. New England Journal of Medicine. 381:191-193. 2019
- Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. JACC: Heart Failure. 7:586-598. 2019
- Effectiveness of single‐ vs dual‐coil implantable defibrillator leads: An observational analysis from the SIMPLE study. Journal of Cardiovascular Electrophysiology. 30:1078-1085. 2019
- Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal. 213:35-46. 2019
- Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Europace. 21:1023-1030. 2019
- Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. JAMA Neurology. 76:764-764. 2019
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology. 73:3271-3280. 2019
- Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 139:2846-2856. 2019
- Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA cardiology. 4:526-526. 2019
- Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?. European Heart Journal. 40:1466-1471. 2019
- Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. Journal of the American College of Cardiology. 73:2243-2250. 2019
- Stroke prevention in patients from Latin American countries with non‐valvular atrial fibrillation: Insights from the GARFIELD‐AF registry. Clinical Cardiology. 42:553-560. 2019
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 380:1326-1335. 2019
- Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke. 14:270-281. 2019
- The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED). Annals of Emergency Medicine. 73:382-392. 2019
- Atrial fibrillation detected initially during acute medical illness: A systematic review. European Heart Journal: Acute Cardiovascular Care. 8:130-141. 2019
- Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons. Europace. 21:445-450. 2019
- Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure. Journal of the American Medical Association (JAMA). 321:753-753. 2019
- Stroke Outcomes in the COMPASS Trial. Circulation. 139:1134-1145. 2019
- Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds. Circulation. 139:757-759. 2019
- Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association. 8:e010510. 2019
- When and how should we cluster and cross over: methodological and ethical issues (letter 1). Canadian Journal of Anaesthesia. 66:234-236. 2019
- When and how should we cluster and cross over: methodological and ethical issues (letter 2). Canadian Journal of Anaesthesia. 66:237-238. 2019
- Defibrillation testing and clinical outcomes after implantable cardioverter–defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. Heart Rhythm. 16:83-90. 2019
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology. 73:121-130. 2019
- Prevention of Arrhythmia Device Infection Trial. Journal of the American College of Cardiology. 72:3098-3109. 2018
- Prevention of Infections in Cardiac Surgery study (PICS): study protocol for a pragmatic cluster-randomized factorial crossover pilot trial. Trials. 19:688. 2018
- Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurology. 17:1053-1060. 2018
- Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). European Heart Journal. 39:3973-3979. 2018
- 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology. 34:1371-1392. 2018
- Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 70:828-835. 2018
- Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation: an analysis from the SIMPLE study. Europace. 20:1798-1803. 2018
- Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow‐up cohort study. Clinical Cardiology. 41:1273-1280. 2018
- Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 72:255-267. 2018
- Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran. Digestive Diseases and Sciences. 63:1878-1889. 2018
- Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). American Heart Journal. 201:160-163. 2018
- The role of randomized cluster crossover trials for comparative effectiveness testing in anesthesia: design of the Benzodiazepine-Free Cardiac Anesthesia for Reduction in Postoperative Delirium (B-Free) trial. Canadian Journal of Anaesthesia. 65:813-821. 2018
- Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine. 378:2191-2201. 2018
- Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. Journal of Stroke and Cerebrovascular Diseases. 27:1673-1682. 2018
- Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. The Lancet. 391:2325-2334. 2018
- Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. Open Heart. 5:e000800-e000800. 2018
- Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. Journal of the American College of Cardiology. 71:2603-2611. 2018
- A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal. 199:51-58. 2018
- Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. American Heart Journal. 199:75-82. 2018
- Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology. 71:2306-2315. 2018
- Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. American Heart Journal. 198:169-177. 2018
- Benzodiazepine administration during adult cardiac surgery: a survey of current practice among Canadian anesthesiologists working in academic centres. Canadian Journal of Anaesthesia. 65:263-271. 2018
- Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE‐LY trial. Journal of Internal Medicine. 283:282-292. 2018
- Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). Canadian Journal of Cardiology. 34:295-302. 2018
- Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. BMJ Open. 8:e017765-e017765. 2018
- External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. European Heart Journal. 39:750-757a. 2018
- Implantable cardioverter–defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. Heart Rhythm. 15:386-392. 2018
- Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). American Journal of Cardiology. 121:584-589. 2018
- A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. European Heart Journal. 39:477-485. 2018
- Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal. 39:464-473. 2018
- Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 20:253-262. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (vol 391, pg 205, 2017). The Lancet. 391:204-204. 2018
- Atrial fibrillation occurring transiently with stress. Current Opinion in Cardiology. 33:58-65. 2018
- Identifying and Treating Young Patients at Risk for Cardiovascular Events. Journal of the American College of Cardiology. 71:303-305. 2018
- Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. Circulation: Cardiovascular Interventions. 11:e005795. 2018
- Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE. 13:e0191592-e0191592. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:219-229. 2018
- Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 7:e017157-e017157. 2017
- Thoracoscopic Left Atrial Appendage Occlusion. JACC: Clinical Electrophysiology. 3:1366-1368. 2017
- Another Dimension of Safety in the Prescription of Anticoagulants for Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology. 70:2633-2635. 2017
- Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta‐analysis. European Journal of Heart Failure. 19:1427-1443. 2017
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- Subclinical Atrial Fibrillation in Older Patients. Circulation. 136:1276-1283. 2017
- Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace. 19:1630-1636. 2017
- Violence, politics and Catholicism in Ireland. By Oliver P. Rafferty sj . Pp. 247. Dublin–Portland, Or: Four Courts Press, 2016. £40. 978 1 84682 583 5. The Journal of Ecclesiastical History. 68:894-896. 2017
- Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. American Heart Journal. 190:94-103. 2017
- Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology. 33:1027-1035. 2017
- Discovering the end of time. Irish Evangelicals in the age of Daniel O'Connell. The Journal of Ecclesiastical History. 68:652-654. 2017
- Effects of dabigatran according to age in atrial fibrillation. Heart. 103:1015-1023. 2017
- Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. American Heart Journal. 189:137-145. 2017
- Religion and greater Ireland. Christianity and Irish global networks, 1750-1950. The Journal of Ecclesiastical History. 68:652-654. 2017
- Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. Cardiovascular Drugs and Therapy. 31:295-301. 2017
- Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm. 14:801-807. 2017
- Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. Europace. 19:euw116-euw116. 2017
- Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. European Heart Journal. 38:1339-1344. 2017
- Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. JAMA cardiology. 2:566-566. 2017
- Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. Clinical Gastroenterology and Hepatology. 15:682-690. 2017
- Embolic Stroke of Undetermined Source. Stroke. 48:867-872. 2017
- Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 7:e014579-e014579. 2017
- The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. JAMA cardiology. 2:324-324. 2017
- Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 103:307-314. 2017
- Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. Europace. 19:euw221-euw221. 2017
- Andexanet Alfa for Factor Xa Inhibitor Reversal. New England Journal of Medicine. 375:2498-2500. 2016
- Anticoagulant-Related Bleeding and Mortality ∗. Journal of the American College of Cardiology. 68:2522-2524. 2016
- High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. Open Heart. 3:e000515-e000515. 2016
- Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 134:1697-1707. 2016
- Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal. 37:2882-2889. 2016
- 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology. 32:1170-1185. 2016
- Preaching in Belfast, 1747–72. A selection of the sermons of James Saurin. Edited by Raymond Gillespie and Roibeard Ó Gallachóir . Pp. 294 incl. 1 frontispiece and 7 ills. Portland–Dublin: Four Courts Press (in association with The Representative Church Body Library), 2015. £50. 978 1 84682 535 4. The Journal of Ecclesiastical History. 67:911-911. 2016
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 375:1131-1141. 2016
- Global Survey of the Frequency of Atrial Fibrillation–Associated Stroke. Stroke. 47:2197-2202. 2016
- Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. The Lancet. 388:1161-1169. 2016
- Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European Stroke Journal. 1:146-154. 2016
- Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. Circulation. 134:589-598. 2016
- Toward Fairness in Data Sharing. New England Journal of Medicine. 375:405-407. 2016
- Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists. British Journal of Haematology. 174:610-623. 2016
- Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. American Heart Journal. 178:145-150. 2016
- Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 17:1425-1439. 2016
- Descendancy. Irish Protestant histories since 1795. By David Fitzpatrick. Pp. ix + 271 incl. 9 charts. Cambridge: Cambridge University Press, 2014. £65. 978 1 107 08093 5. The Journal of Ecclesiastical History. 67:675-676. 2016
- Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. International Journal of Stroke. 11:526-533. 2016
- Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace. 18:973-978. 2016
- Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. European Journal of Epidemiology (EJE). 31:541-561. 2016
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. The Lancet. 387:2302-2311. 2016
- Apical versus Non‐Apical Lead: Is ICD Lead Position Important for Successful Defibrillation?. Journal of Cardiovascular Electrophysiology. 27:581-586. 2016
- An Irish-Speaking Island: State, Religion, Community and the Linguistic Landscape in Ireland, 1770–1870, by Nicholas M. Wolf. English Historical Review. 131:473-474. 2016
- Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. Thrombosis Research. 140:81-88. 2016
- Subclinical Atrial Fibrillation and the Risk of Stroke (vol 366, pg 120, 2012). New England Journal of Medicine. 374:998-998. 2016
- Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. Journal of the American College of Cardiology. 67:1300-1308. 2016
- Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol. BMJ Open. 6:e009364-e009364. 2016
- Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. Thrombosis Research. 139:77-81. 2016
- Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. Heart Rhythm. 13:504-510. 2016
- D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. Thrombosis and Haemostasis. 115:921-930. 2016
- Dabigatran etexilate and reduction in serum apolipoprotein B. Heart. 102:57-62. 2016
- Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age and Ageing. 45:77-83. 2016
- Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE. 11:e0164076-e0164076. 2016
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. New England Journal of Medicine. 373:2413-2424. 2015
- Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. American Heart Journal. 170:1151-1160. 2015
- Reply. Journal of the American College of Cardiology. 66:2682-2682. 2015
- Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). American Journal of Cardiology. 116:1204-1209. 2015
- Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. International Journal of Cardiology. 196:127-131. 2015
- Global Survey of the Diagnostic Evaluation and Management of Cryptogenic Ischemic Stroke. International Journal of Stroke. 10:1031-1036. 2015
- Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. Heart Rhythm. 12:2148-2154. 2015
- Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. New England Journal of Medicine. 373:1295-1306. 2015
- Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. Circulation. 132:796-803. 2015
- Resetting of a Supraventricular Tachycardia by a Ventricular Premature Beat. What is the Mechanism?. PACE - Pacing and Clinical Electrophysiology. 38:1005-1008. 2015
- The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. European Heart Journal. 36:1640-1642. 2015
- Letter by Longtin et al Regarding Article, “Rates of and Factors Associated With Infection in 200 909 Medicare Implantable Cardioverter-Defibrillator Implants: Results From the National Cardiovascular Data Registry”. Circulation. 131:e517. 2015
- Changes in Renal Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 65:2481-2493. 2015
- Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial. Journal of Thrombosis and Haemostasis. 13:699-707. 2015
- Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Thrombosis and Haemostasis. 113:625-632. 2015
- Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation. Cardiovascular Quality and Outcomes. 8:S12-S20. 2015
- Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. Stroke. 46:667-672. 2015
- Response to Letter Regarding Article “Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events”. Circulation. 131:e337-e338. 2015
- Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). The Lancet. 385:785-791. 2015
- Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. European Heart Journal. 36:281-288. 2015
- Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS<sub>2</sub> Score. Circulation Journal. 79:2138-2147. 2015
- Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis. PLoS ONE. 10:e0129282-e0129282. 2015
- Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiology Research. 6:267-277. 2015
- Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. Open Cardiovascular Medicine Journal. 8:113-120. 2014
- Efficacy and Safety of Dronedarone in Patients Previously Treated With Other Antiarrhythmic Agents. Clinical Cardiology. 37:717-724. 2014
- Interaction Between Digoxin and Dronedarone in the PALLAS Trial. Circulation: Arrhythmia and Electrophysiology. 7:1019-1025. 2014
- Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. Heart Rhythm. 11:2156-2162. 2014
- Response to Letter Regarding Article, “Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis”. Circulation. 130:e195. 2014
- Additional Events in the RE-LY Trial. New England Journal of Medicine. 371:1464-1465. 2014
- 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology. 30:1114-1130. 2014
- Embolic strokes of undetermined source: support for a new clinical construct–Authors' reply. Lancet Neurology. 13:967-967. 2014
- Predictors of Mortality in Patients With Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial. Stroke. 45:2989-2994. 2014
- Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study. Open Cardiovascular Medicine Journal. 8:94-101. 2014
- Predictors of early and late stroke following cardiac surgery. CANADIAN MEDICAL ASSOCIATION JOURNAL. 186:905-911. 2014
- Response to Letter Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”. Circulation. 130:e95. 2014
- Association of cyclooxygenase-2 genetic variant with cardiovascular disease. European Heart Journal. 35:2242-2248. 2014
- Response to Letter Regarding Article, “Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study”. Circulation. 130:e85. 2014
- An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. Europace. 16:1117-1124. 2014
- Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 100:1193-1200. 2014
- Switching Patients From Blinded Study Drug to Warfarin at the End of the ENGAGE AF–TIMI 48 Trial. Journal of the American College of Cardiology. 64:585-587. 2014
- Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. European Heart Journal. 35:1856-1863. 2014
- Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. European Heart Journal. 35:1831-1833. 2014
- Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation. Stroke. 45:2127-2130. 2014
- Reply. Journal of the American College of Cardiology. 63:2885-2886. 2014
- Reply: regarding the effect of dabigatran plasma concentrations.. Journal of the American College of Cardiology. 63:2885-2886. 2014
- Real-world experience with atrial fibrillation ablation: cause for concern. European Heart Journal. 35:1430-1432. 2014
- Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation. 129:2094-2099. 2014
- Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. Heart Failure Reviews. 19:305-313. 2014
- Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. Journal of Thrombosis and Thrombolysis. 37:435-442. 2014
- Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. Circulation. 129:1568-1576. 2014
- Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurology. 13:429-438. 2014
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation. 129:961-970. 2014
- Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Journal of Vascular Surgery. 59:871-872. 2014
- Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2). Journal of the American Medical Association (JAMA). 311:692-692. 2014
- Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. ACP journal club. 160:JC4-JC4. 2014
- Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace. 16:174-181. 2014
- Efficacy and Safety of Warfarin VS. Antiplatelet Therapy in Patients with Systolic Heart Failure and Sinus Rhythm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Stroke. 9:199-206. 2014
- Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). American Journal of Cardiology. 113:669-675. 2014
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. Journal of the American College of Cardiology. 63:321-328. 2014
- Patient outcomes using the European label for dabigatran. Thrombosis and Haemostasis. 112:933-942. 2014
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 369:2093-2104. 2013
- Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation. 128:2325-2332. 2013
- Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation. 128:2192-2201. 2013
- Left Atrial Appendage Occlusion Study II (LAAOS II). Canadian Journal of Cardiology. 29:1443-1447. 2013
- Primary Prevention Ethnic Differences in the Risk of Stroke in Atrial Fibrillation. Aktuelle Neurologie. 40:E44-E44. 2013
- Primary Prevention Long-Term Observational Study with Dabigatran in Atrial Fibrillation. Aktuelle Neurologie. 40:E45-E45. 2013
- Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study. International Journal of Cardiology. 168:2540-2547. 2013
- Cost-Effectiveness of Dronedarone in Patients With Atrial Fibrillation in the ATHENA Trial. Canadian Journal of Cardiology. 29:1249-1255. 2013
- Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. New England Journal of Medicine. 369:1206-1214. 2013
- Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. Journal of the American College of Cardiology. 62:900-908. 2013
- Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE‐LY trial. European Journal of Heart Failure. 15:1053-1061. 2013
- The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. European Heart Journal. 34:2752-2759. 2013
- Right Ventricular Tachycardia. Circulation. 128:e85-e87. 2013
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 128:237-243. 2013
- Dabigatran Versus Warfarin. Stroke. 44:1891-1896. 2013
- Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. International Journal of Clinical Practice. 67:516-526. 2013
- Randomized Cluster Crossover Trials for Reliable, Efficient, Comparative Effectiveness Testing: Design of the Prevention of Arrhythmia Device Infection Trial (PADIT). Canadian Journal of Cardiology. 29:652-658. 2013
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). European Heart Journal. 34:1498-1505. 2013
- Atrial fibrillation is associated with increased mortality: causation or association?. European Heart Journal. 34:1027-1030. 2013
- Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. Circulation. 127:1404-1412. 2013
- Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. Journal of Cardiovascular Electrophysiology. 24:381-387. 2013
- Response to Letters Regarding Article, “Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”. Circulation. 127:E506-E506. 2013
- Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.. Circulation. 127:e506. 2013
- Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial. Clinical Gastroenterology and Hepatology. 11:246-252.e5. 2013
- Reply to the Editor—Shocks and Mortality versus Pacing and Mortality. Heart Rhythm. 10:e9-e10. 2013
- Response to Letter Regarding Article, “Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation: Results From the Resynchronization for Ambulatory Heart Failure Trial (RAFT)”. Circulation. Heart Failure. 6:23-24. 2013
- Shocks and Mortality versus Pacing and Mortality Reply. Heart Rhythm. 10:E9-E10. 2013
- Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation. 127:634-640. 2013
- Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. Journal of Thrombosis and Thrombolysis. 35:295-301. 2013
- Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation. Clinical Cardiology. 36:88-95. 2013
- Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS 2 and CHA 2 DS 2 -VASc Scores in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 6:31-38. 2013
- Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. Canadian Journal of Cardiology. 29:224-228. 2013
- Response to Letter Regarding Article, “Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy”. Circulation. 127:e278-e279. 2013
- The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. European Heart Journal. 34:170-176. 2013
- A Randomized‐Controlled Pilot Study Comparing ICD Implantation with and Without Intraoperative Defibrillation Testing in Patients with Heart Failure and Severe Left Ventricular Dysfunction: A Substudy of the RAFT Trial. Journal of Cardiovascular Electrophysiology. 23:1313-1316. 2012
- Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. Stroke. 43:3291-3297. 2012
- Implantable cardioverter-defibrillator shock prevention does not reduce mortality: A systemic review. Heart Rhythm. 9:2068-2074. 2012
- Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. Circulation. 126:2309-2316. 2012
- Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. Heart Rhythm. 9:1667-1673. 2012
- Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Circulation. Heart Failure. 5:566-570. 2012
- Reply to the Editor—Electrogram Confirmation of Atrial High-Rate Episodes. Heart Rhythm. 9:e17-e18. 2012
- Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. Heart Rhythm. 9:1241-1246. 2012
- Relevance of Electrical Remodeling in Human Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 5:626-631. 2012
- Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases. 21:429-435. 2012
- The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: A randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. American Heart Journal. 164:146-152. 2012
- Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update. Journal of Cardiovascular Electrophysiology. 23:890-923. 2012
- Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation. 126:343-348. 2012
- Age and Mental Health Predict Early Device-Specific Quality of Life in Patients Receiving Prophylactic Implantable Defibrillators. Canadian Journal of Cardiology. 28:502-507. 2012
- A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). American Heart Journal. 163:931-937.e1. 2012
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. Stroke. 43:1511-1517. 2012
- Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. Thrombosis Research. 129:715-719. 2012
- Permanent Pacemaker Therapy for Neurally Mediated Syncope. Circulation. 125:2552-2553. 2012
- Warfarin in Heart Failure. New England Journal of Medicine. 366:1936-1938. 2012
- Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. Journal of Cardiovascular Electrophysiology. 23:462-472. 2012
- Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Haemostasis. 10:966-968. 2012
- Letter by Van de Werf et al Regarding Article, “Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians”. Stroke. 43:e46-e47. 2012
- Subclinical Atrial Fibrillation and the Risk of Stroke REPLY. New England Journal of Medicine. 366:1352-1353. 2012
- The authors reply. New England Journal of Medicine. 366:1352-1353. 2012
- Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation. 125:1605-1616. 2012
- Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. Circulation. Genomic and precision medicine. 5:250-256. 2012
- Dronedarone in High-Risk Permanent Atrial Fibrillation REPLY. New England Journal of Medicine. 366:1161-1161. 2012
- Eculizumab in a Patient with Dense-Deposit Disease. New England Journal of Medicine. 366:1161-1163. 2012
- Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurology. 11:225-231. 2012
- Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal. Journal of Thrombosis and Haemostasis. 10:502-504. 2012
- Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 119:2172-2174. 2012
- Dronedarone in High-Risk Permanent Atrial Fibrillation (vol 365, pg 2268, 2011). New England Journal of Medicine. 366:672-672. 2012
- Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation. 125:669-676. 2012
- Are Elderly Patients at Increased Risk of Complications Following Pacemaker Implantation? A Meta‐Analysis of Randomized Trials. PACE - Pacing and Clinical Electrophysiology. 35:131-134. 2012
- Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm. 9:217-224.e2. 2012
- Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation. Journal of the American College of Cardiology. 59:854-855. 2012
- Reply to Letters Regarding Article, “Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial”. Circulation. 125:E293-E294. 2012
- Subclinical Atrial Fibrillation and the Risk of Stroke. New England Journal of Medicine. 366:120-129. 2012
- Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thrombosis and Haemostasis. 108:1228-1235. 2012
- The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial. Canadian Journal of Cardiology. 28:95-101. 2012
- Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine. 365:2268-2276. 2011
- Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. Circulation. 124:2649-2660. 2011
- Antiarrhythmic Drug Therapy for New-Onset Ventricular Arrhythmia (VT/VF) in ICD Patients. Cardiac Electrophysiology Clinics. 3:651-661. 2011
- Computerized clinical decision support systems for therapeutic drug monitoring and dosing: A decision-maker-researcher partnership systematic review. Implementation Science. 6:90. 2011
- Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial. ACP journal club. 155:660-660. 2011
- Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. ACP journal club. 155:579-579. 2011
- Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial. Journal of Thrombosis and Haemostasis. 9:2168-2175. 2011
- Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. European Heart Journal. 32:2347-2349. 2011
- Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace. 13:1118-1126. 2011
- Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies. Journal of Cardiovascular Electrophysiology. 22:770-776. 2011
- Apixaban in Patients with Atrial Fibrillation REPLY. New England Journal of Medicine. 364:2363-2364. 2011
- The authors reply. New England Journal of Medicine. 364:2363-2364. 2011
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. Circulation. 123:2363-2372. 2011
- Rhythm- and Rate-Controlling Effects of Dronedarone in Patients With Atrial Fibrillation (from the ATHENA Trial). American Journal of Cardiology. 107:1019-1022. 2011
- Irbesartan in Patients with Atrial Fibrillation. New England Journal of Medicine. 364:928-938. 2011
- Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 364:806-817. 2011
- Contralateral Pneumothorax in Left Sided CRT Device Implantation.. Indian Pacing and Electrophysiology Journal. 11:16-19. 2011
- Advances in treatment and management. Nature Reviews Cardiology. 8:67-68. 2011
- Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. Circulation. 123:131-136. 2011
- Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. Canadian Journal of Cardiology. 27:74-90. 2011
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thrombosis and Haemostasis. 105:908-919. 2011
- Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (vol 9, pg 1157, 2010). Lancet Neurology. 10:27-27. 2011
- Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -. Circulation Journal. 75:800-805. 2011
- Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction. Circulation. 122:2645-2652. 2010
- Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. New England Journal of Medicine. 363:2385-2395. 2010
- Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurology. 9:1157-1163. 2010
- Defibrillation Testing at the Time of ICD Insertion: An Analysis From the Ontario ICD Registry. Journal of Cardiovascular Electrophysiology. 21:1344-1348. 2010
- Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. American Heart Journal. 160:1178-1184. 2010
- Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation. Circulation. 122:2246-2253. 2010
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation (vol 361, pg 1139, 2009). New England Journal of Medicine. 363:1877-1877. 2010
- Newly Identified Events in the RE-LY Trial. New England Journal of Medicine. 363:1875-1876. 2010
- A rare cause of implantable cardioverter-defibrillator failure: Short-circuiting via an unused pace/sense lead. Heart Rhythm. 7:1630-1631. 2010
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment. New England Journal of Medicine. 363:1704-1714. 2010
- Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology. 56:1353-1354. 2010
- Antiarrhythmic use from 1991 to 2007: Insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm. 7:1171-1177. 2010
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. The Lancet. 376:975-983. 2010
- Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. European Heart Journal. 31:2133-2140. 2010
- Lenient rate control is as effective as strict rate control for preventing cardiovascular events in AF. ACP journal club. 153:JC2-JC2. 2010
- Dronedarone in patients with congestive heart failure: insights from ATHENA. European Heart Journal. 31:1717-1721. 2010
- Device‐Related Infection Among Patients With Pacemakers and Implantable Defibrillators: Incidence, Risk Factors, and Consequences. Journal of Cardiovascular Electrophysiology. 21:786-790. 2010
- Explaining the RE-LY Trial. Hospital Pharmacist. 63:334-336. 2010
- Correction. Journal of the American College of Cardiology. 55:2788-2788. 2010
- Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal. Journal of Thrombosis and Haemostasis. 8:1438-1439. 2010
- Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. Circulation. Cardiovascular Quality and Outcomes. 3:277-283. 2010
- Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology. 55:1796-1802. 2010
- Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thrombosis Research. 125:e128-e131. 2010
- Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal. 159:348-353.e1. 2010
- Canadian Registry of ICD Implant Testing Procedures (CREDIT): Current Practice, Risks, and Costs of Intraoperative Defibrillation Testing. Journal of Cardiovascular Electrophysiology. 21:177-182. 2010
- Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. Journal of Thrombosis and Haemostasis. 8:101-106. 2010
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis. 104:633-641. 2010
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation REPLY. New England Journal of Medicine. 361:2674-2675. 2009
- The authors reply. New England Journal of Medicine. 361:2674-2675. 2009
- Assessment of Resynchronization Therapy on Functional Status and Quality of Life in Patients Requiring an Implantable Defibrillator. PACE - Pacing and Clinical Electrophysiology. 32:1509-1519. 2009
- Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin. Circulation. 120:1927-1932. 2009
- Left Atrial Appendage Occlusion Eliminates the Need for Warfarin. Circulation. 120:1919-1926. 2009
- Left Atrial Appendage Occlusion Eliminates the Need for Warfarin Response to Holmes and Schwartz. Circulation. 120:1926-1926. 2009
- Effect of Metoprolol on Quality of Life in the Prevention of Syncope Trial. Journal of Cardiovascular Electrophysiology. 20:1083-1088. 2009
- Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter. Circulation. 120:1174-1180. 2009
- Clopidogrel plus aspirin in atrial fibrillation.. New England Journal of Medicine. 361:1314. 2009
- The authors reply. New England Journal of Medicine. 361:1314-1315. 2009
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 361:1139-1151. 2009
- Atrial overdrive pacing in sleep apnoea: a meta-analysis. Europace. 11:1037-1040. 2009
- Design and Use of a Quantitative Scale for Measuring Presyncope. Journal of Cardiovascular Electrophysiology. 20:888-893. 2009
- Dronedarone in Atrial Fibrillation REPLY. New England Journal of Medicine. 360:2480-2481. 2009
- Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation (vol 360, pg 668, 2009). New England Journal of Medicine. 360:2487-2487. 2009
- The authors reply. New England Journal of Medicine. 360:2480-2481. 2009
- A Case of Long‐RP Tachycardia: What is the Mechanism?. Journal of Cardiovascular Electrophysiology. 20:702-704. 2009
- Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. New England Journal of Medicine. 360:2066-2078. 2009
- Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal. 157:805-810.e2. 2009
- Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation. Stroke. 40:1410-1416. 2009
- Effect of dronedarone on cardiovascular events in atrial fibrillation. Revista Portuguesa de Cardiologia. 28:345-347. 2009
- Postoperative Low‐Molecular‐Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology. 32:378-382. 2009
- Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine. 360:668-678. 2009
- Prevention of Atrial Fibrillation. Circulation. 119:606-618. 2009
- A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 20:138-144. 2009
- Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes. Heart. 95:95-97. 2009
- Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design. Current Opinion in Cardiology. 24:1-8. 2009
- Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Circulation. 118:2029-2037. 2008
- Life and Death after ICD Implantation. New England Journal of Medicine. 359:1058-1059. 2008
- Narrow QRS tachycardia with long R–P. International Journal of Cardiology. 127:e57-e60. 2008
- Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal. 156:37-43. 2008
- Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. New England Journal of Medicine. 358:2667-2677. 2008
- Atrial deformation: the key to maintenance of sinus rhythm in patients with atrial fibrillation?. European Heart Journal. 29:1483-1484. 2008
- Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation. Stroke. 39:1901-1910. 2008
- Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005. American Heart Journal. 155:829-840. 2008
- Potential demographic and baselines variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator — A prognostic indicator. International Journal of Cardiology. 126:101-107. 2008
- Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. Stroke. 39:1482-1486. 2008
- Response to Letter Regarding Article, “Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation”. Circulation. 117:E150-E150. 2008
- Azimilide for the Treatment of Atrial Fibrillation, Atrial Flutter, and Paroxysmal Supraventricular Tachycardia: Results of a Randomized Trial and Insights on the Concordance of Symptoms and Recurrent Arrhythmias. Journal of Cardiovascular Electrophysiology. 19:172-177. 2008
- Should patients with cardiovascular disease take fish oil?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 178:181-182. 2008
- Rationale and Design of ATHENA: A Placebo‐Controlled, Double‐Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg Bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter. Journal of Cardiovascular Electrophysiology. 19:69-73. 2008
- Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. Journal of the American College of Cardiology. 50:2156-2161. 2007
- Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. New England Journal of Medicine. 357:987-999. 2007
- Worsening of Symptoms Before Presentation with Vasovagal Syncope. Journal of Cardiovascular Electrophysiology. 18:954-959. 2007
- Independent predictors of stroke in patients with atrial fibrillation. Neurology. 69:546-554. 2007
- The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: A substudy of the Canadian Trial of Physiological Pacing (CTOPP). Heart Rhythm. 4:1024-1028. 2007
- Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. Circulation. 116:449-455. 2007
- Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. European Heart Journal. 28:1746-1749. 2007
- Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. Journal of Hypertension. 25:307-313. 2007
- Prevention of vascular events in atrial fibrillation – Authors' reply. The Lancet. 369:106-106. 2007
- Omega-3 fatty acids and sudden arrhythmic death.. Herz. 31 Suppl 3:59-64. 2006
- Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. American Heart Journal. 152:967-973. 2006
- Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks—Reply. Journal of the American Medical Association (JAMA). 296:1229-1229. 2006
- In reply [3]. Journal of the American Medical Association (JAMA). 296:1230. 2006
- ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). American Heart Journal. 152:442-447. 2006
- Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold. Circulation. 114:104-109. 2006
- Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing. Circulation. 114:11-17. 2006
- Efficacy of Azimilide for the Maintenance of Sinus Rhythm in Patients With Paroxysmal Atrial Fibrillation in the Presence and Absence of Structural Heart Disease. American Journal of Cardiology. 98:215-218. 2006
- Benefits of left atrial appendage occlusion. American Heart Journal. 151:e3-e3. 2006
- Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. The Lancet. 367:1903-1912. 2006
- Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. American Heart Journal. 151:1187-1193. 2006
- Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.. American Heart Journal. 151:1043-1049. 2006
- Stroke prevention in patients with atrial fibrillation: The diagnosis and management of hypertension by specialists. Canadian Journal of Cardiology. 22:485-488. 2006
- Prevention of Syncope Trial (POST). Circulation. 113:1164-1170. 2006
- Use and Misuse of Surrogate Outcomes in Arrhythmia Trials. Circulation. 113:764-766. 2006
- Use and misuse of surrogate outcomes in arrhythmia trials. Circulation. 113:764-766. 2006
- Diagnostic criteria for vasovagal syncope based on a quantitative history. European Heart Journal. 27:344-350. 2006
- Reply. Journal of the American College of Cardiology. 47:890-891. 2006
- Comparison of β-Blockers, Amiodarone Plus β-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators<SUBTITLE>The OPTIC Study: A Randomized Trial</SUBTITLE>. Journal of the American Medical Association (JAMA). 295:165-165. 2006
- Age of First Faint in Patients with Vasovagal Syncope. Journal of Cardiovascular Electrophysiology. 17:49-54. 2006
- Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction - A combined analysis from multicenter trials. Clinical Cardiology. 28:471-478. 2005
- William Kelly and John R. Young, eds. Ulster and Scotland, 1600–2000: History, Language and Identity. Dublin: Four Courts Press, 2004. Pp. 189. $55.00 (cloth).. Journal of British Studies. 44:828-829. 2005
- Therapies for the prevention of stroke and other vascular events in atrial fibrillation and atrial flutter.. Canadian Journal of Cardiology. 21 Suppl B:71B-73B. 2005
- Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. American Heart Journal. 150:288-293. 2005
- Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. European Heart Journal. 26:1385-1393. 2005
- Timing of arrhythmic death after myocardial infarction: does it affect timing of ICD implantation?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal. 26:1350-1352. 2005
- Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. American Heart Journal. 149:1020-1034. 2005
- Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Journal of the American College of Cardiology. 45:1832-1839. 2005
- Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart. 91:618-623. 2005
- Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. European Heart Journal, Supplement. 7:C28-C33. 2005
- Implantable Cardioverter–Defibrillator Therapy after Myocardial Infarction. New England Journal of Medicine. 352:1039-1041. 2005
- Implantable cardioverter-defibrillator therapy after myocardial infarction - Reply. New England Journal of Medicine. 352:1040-1041. 2005
- Cost-effectiveness of physiologic pacing: Results of the Canadian Health Economic Assessment of Physiologic Pacing. Heart Rhythm. 2:270-275. 2005
- Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: Results from the Canadian Registry of Atrial Fibrillation. American Heart Journal. 149:489-496. 2005
- Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.. Current Opinion in Cardiology. 20:31-37. 2005
- Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction. New England Journal of Medicine. 351:2481-2488. 2004
- Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm. 1:540-547. 2004
- Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. CANADIAN MEDICAL ASSOCIATION JOURNAL. 171:1053-1056. 2004
- The association of left atrial size and occurrence of atrial fibrillation: A prospective cohort study from the Canadian Registry of Atrial Fibrillation. American Heart Journal. 148:649-654. 2004
- The management of patients with carotid sinus syndrome: is pacing the answer?. Clinical Autonomic Research. 14:i80-i86. 2004
- Metoprolol prophylaxis against postoperative atrial fibrillation increases length of hospital stay in patients not on pre-operative blockers: the blocker length of stay (BLOS) trial. Heart. 90:941-942. 2004
- Role of oral anticoagulation in management of atrial fibrillation. Heart. 90:813-817. 2004
- Physiologic pacing: where pacing mode selection reflects the indication. Heart. 90:593-594. 2004
- Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. American Heart Journal. 147:837-840. 2004
- Prognostic differences between atrial fibrillation and atrial flutter. American Journal of Cardiology. 93:647-649. 2004
- Atrial fibrillation: guiding lessons from epidemiology. Cardiology Clinics. 22:1-8. 2004
- Canadian Trial of Physiological Pacing. Circulation. 109:357-362. 2004
- Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in. Journal of Interventional Cardiac Electrophysiology. 7:374-378. 2003
- Second Vasovagal Pacemaker Study (VPS II): Rationale, Design, Results, and Implications for Practice and Future Clinical Trials. Journal of Interventional Cardiac Electrophysiology. 7:411-415. 2003
- The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Rationale, Design and Specific Aims. Journal of Interventional Cardiac Electrophysiology. 7:447-451. 2003
- Clinical review of radiofrequency catheter ablation for cardiac arrhythmias.. Canadian Journal of Cardiology. 19:1273-1284. 2003
- Ethical Aspects in Trials of Implantable Medical Devices. Journal of the American Medical Association (JAMA). 290:1579-1579. 2003
- Ethical Aspects in Trials of Implantable Medical Devices—Reply. Journal of the American Medical Association (JAMA). 290:1579-1579. 2003
- Combined Antiplatelet Therapy in Atrial Fibrillation:. Journal of Cardiovascular Electrophysiology. 14:S60-S63. 2003
- Introduction. Journal of Cardiovascular Electrophysiology. 14:S1-S1. 2003
- Prevention of Vascular Events in Patients with Atrial Fibrillation:. Journal of Cardiovascular Electrophysiology. 14:S52-S55. 2003
- Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. American Heart Journal. 146:489-493. 2003
- Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target.. American Journal of Cardiology. 91:9G-14G. 2003
- Pacemaker Therapy for Prevention of Syncope in Patients With Recurrent Severe Vasovagal Syncope. Journal of the American Medical Association (JAMA). 289:2224-2224. 2003
- Asymptomatic or “Silent” Atrial Fibrillation. Circulation. 107:1141-1145. 2003
- Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. American Heart Journal. 145:430-437. 2003
- Long-term amiodarone therapy and the risk of complications after cardiac surgery: Results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). Journal of Thoracic and Cardiovascular Surgery. 125:633-637. 2003
- Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts. American Heart Journal. 145:418-423. 2003
- Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: The β-Blocker Length Of Stay (BLOS) study. American Heart Journal. 145:226-232. 2003
- Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions.. Journal of Interventional Cardiac Electrophysiology. 7:189-192. 2003
- Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. American Heart Journal. 145:174-178. 2003
- Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope Rationale and study design. Europace. 5:71-75. 2003
- Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation. Journal of the American Medical Association (JAMA). 288:2441-2441. 2002
- Quality of life in the Canadian Implantable Defibrillator Study (CIDS). American Heart Journal. 144:282-289. 2002
- Quality of life in the Canadian Implantable Defibrillator Study (CIDS). American Heart Journal. 144:282-289. 2002
- Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.. Clinical Respiratory Journal. 106:75-80. 2002
- Historical criteria that distinguish syncope from seizures. Journal of the American College of Cardiology. 40:142-148. 2002
- Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. American Heart Journal. 143:984-990. 2002
- Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. American Heart Journal. 143:643-649. 2002
- Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation. Journal of Clinical Pharmacology. 42:388-394. 2002
- Evolution of the implantable cardioverter defibrillator. The Lancet. 359:1362-1363. 2002
- Beta-blockers in syncope: the jury is still out. Journal of the American College of Cardiology. 38:2135-2135. 2001
- Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. American Journal of Cardiology. 88:974-979. 2001
- Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. Circulation. 104:1622-1626. 2001
- Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. Journal of the American College of Cardiology. 38:167-172. 2001
- Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes. Circulation. 103:3081-3085. 2001
- Prophylactic amiodarone in older patients receiving β -blockers and undergoing open-heart surgery was efficacious. Evidence-based Cardiovascular Medicine. 5:39-40. 2001
- New-Onset Atrial Fibrillation. Circulation. 103:2365-2370. 2001
- Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. Circulation. 103:1416-1421. 2001
- Circadian variation of paroxysmal atrial fibrillation. American Journal of Cardiology. 87:794-798. 2001
- Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. European Heart Journal. 21:2071-2078. 2000
- Anticoagulation therapy for patients with atrial fibrillation.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 163:1235. 2000
- Effects of Physiologic Pacing versus Ventricular Pacing. New England Journal of Medicine. 343:1417-1418. 2000
- Effects of physiologic pacing versus ventricular pacing - Reply. New England Journal of Medicine. 343:1418-1418. 2000
- The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Study protocol. American Heart Journal. 140:735-739. 2000
- Chapter 1. Summary of the CCS Consensus Conference on prevention of sudden death from cardiac arrhythmia.. Canadian Journal of Cardiology. 16:1298-1302. 2000
- Summary of the CCS Consensus Conference on Prevention of Sudden Death from Cardiac Arrhythmia. Canadian Journal of Cardiology. 16:1298-1302. 2000
- Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Journal of the American College of Cardiology. 36:794-802. 2000
- Randomized Crossover Comparison of DDDR Versus VDD Pacing After Atrioventricular Junction Ablation for Prevention of Atrial Fibrillation. Circulation. 102:736-741. 2000
- Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation. The atrial pacing peri-ablation for paroxysmal atrial fibrillation (PA (3)) study investigators.. Circulation. 102:736-741. 2000
- The beta-blocker length of stay study (BLOSS) trial: A randomized, placebo-controlled trial of beta-blocker treatment for reduction of hospitalization after cardiac surgery. Journal of the American College of Cardiology. 36:313-314. 2000
- Canadian Cardiovascular Society 1999 consensus conference on prevention of sudden death from ventricular arrhythmia. Canadian Journal of Cardiology. 16:8C-9C. 2000
- Long term management of the survivor of ventricular fibrillation or sustained ventricular tachycardia.. Canadian Journal of Cardiology. 16 Suppl C:20C-22C. 2000
- Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes. New England Journal of Medicine. 342:1385-1391. 2000
- Anticoagulation for patients with atrial fibrillation and risk factors for stroke. The BMJ. 320:1219-1220. 2000
- Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. American Heart Journal. 139:752-760. 2000
- Demographic parameters predict strongly all-cause and arrhythmic mortality in high-risk patients after myocardial infarction in the thrombolytic era - A secondary meta-analysis of survival trials. Heart. 83. 2000
- Disparity in the mortality pattern in recently completed post-myocardial infarction survival trials- A statistical comparison. Heart. 83. 2000
- Left ventricular ejection fraction in the trombolytic era remains a powerful predictor of long-term but not short-term all-cause, cardiac and arrhythmic mortality after myocardial infarction - A secondary meta-analysis of 2828 patients. Heart. 83. 2000
- Identification of Patients Most Likely to Benefit From Implantable Cardioverter-Defibrillator Therapy. Circulation. 101:1660-1664. 2000
- Amiodarone to Prevent Recurrence of Atrial Fibrillation. New England Journal of Medicine. 342:913-920. 2000
- Canadian Implantable Defibrillator Study (CIDS). Circulation. 101:1297-1302. 2000
- CLINICAL TRIALS OF PACING MODE SELECTION. Cardiology Clinics. 18:1-23. 2000
- Why aren't we falling for anticoagulant therapy?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 162:191-192. 2000
- Why aren't we falling for anticoagulant therapy? The author responds. CANADIAN MEDICAL ASSOCIATION JOURNAL. 162:191-192. 2000
- Implantable Cardioverter Defibrillator (ICD) therapy for sudden cardiac death. Canadian Journal of Cardiology. 16:1293-1324. 2000
- Trials of physiologie pacing. Journal of Interventional Cardiac Electrophysiology. 4:156-158. 2000
- Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation. 100:2025-2034. 1999
- Depression and Risk of Sudden Cardiac Death After Acute Myocardial Infarction: Testing for the Confounding Effects of Fatigue. Psychosomatic Medicine. 61:729-737. 1999
- Meta-analysis of antiarrhythmic drug trials. American Journal of Cardiology. 84:90-93. 1999
- Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 161:533-534. 1999
- A peacemaker reduced the recurrence of syncope in patients with severe vasovagal syncope. Evidence-Based Medicine. 4:154. 1999
- Atrial Pacing Periablation for Prevention of Paroxysmal Atrial Fibrillation. Circulation. 99:2553-2558. 1999
- Amiodarone Interaction With β-Blockers. Circulation. 99:2268-2275. 1999
- Appropriate Use of the Implantable Cardioverter Defibrillator: A Canadian Perspective. PACE - Pacing and Clinical Electrophysiology. 22:1-4. 1999
- Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial.. Psychosomatic Medicine. 61:566-575. 1999
- The North American vasovagal pacemaker study (VPS). Journal of the American College of Cardiology. 33:16-20. 1999
- The canadian registry of atrial fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. American Journal of Cardiology. 82:82N-85N. 1998
- Dual-chamber pacing was more effective in patients with sinus-node dysfunction. Evidence-based Cardiovascular Medicine. 2:79-79. 1998
- Implantable cardioverter defibrillators—for whom?. The Lancet. 352:338-340. 1998
- Review: Amiodarone reduces mortality after MI and for congestive heart failure. Evidence-Based Medicine. 3:112-113. 1998
- Evolving Indications for Permanent Pacing in Patients with Vasovagal Syncope. Journal of Interventional Cardiac Electrophysiology. 2:52-53. 1998
- Erratum: Amiodarone reduced ventricular fibrillation or arrhythmic death in MI with frequent ventricular premature depolarizations (Evidence-Based Medicine (September-October 1997) 2:142)). Evidence-Based Medicine. 2:167. 1997
- Definition of Predicted Effective Antiarrhythmic Drug Therapy for Ventricular Tachyarrhythmias by the Electrophysiologic Study Approach: Randomized Comparison of Patient Response Criteria. Journal of the American College of Cardiology. 30:1346-1353. 1997
- Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. The Lancet. 350:1417-1424. 1997
- Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.. The Lancet. 349:1767. 1997
- Amiodarone after myocardial infarction: EMIAT and CAMIAT trials. The Lancet. 349:1769-1770. 1997
- Prophylactic implanted defibrillator may improve survival in patients at high risk for ventricular tachyarrhythmias. Evidence-based Cardiovascular Medicine. 1:46-46. 1997
- North American Vasovagal Pacemaker Study: Study Design and Organization. PACE - Pacing and Clinical Electrophysiology. 20:844-848. 1997
- Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. The Lancet. 349:675-682. 1997
- Comparison of mortality from acute myocardial infarction between 1979 and 1992 in a geographically defined stable population. American Journal of Cardiology. 78:1345-1349. 1996
- How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. JAMA Internal Medicine. 156:2221-2224. 1996
- Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure.. Heart. 76:137-143. 1996
- Dual-Chamber Versus Ventricular Pacing. Circulation. 94:578-583. 1996
- Antithrombotic therapy in atrial fibrillation.. Canadian Family Physician. 42:1341-1345. 1996
- Canadian atrial fibrillation anticoagulation study: were the patients subsequently treated with warfarin? Canadian Atrial Fibrillation Anticoagulation Study Group.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 154:1669-1674. 1996
- [Antithrombotic treatment of atrial fibrillation].. Canadian Journal of Cardiology. 12 Suppl A:14A-18A. 1996
- [Auricular fibrillation and flutter].. Canadian Journal of Cardiology. 12 Suppl A:6A-9A. 1996
- Antithrombotic therapy in atrial fibrillation.. Canadian Journal of Cardiology. 12 Suppl A:17A-20A. 1996
- Atrial fibrillation and atrial flutter.. Canadian Journal of Cardiology. 12 Suppl A:9A-11A. 1996
- The problem of asymptomatic ventricular arrhythmias among survivors of acute myocardial infarction: Role of amiodarone. ACC Current Journal Review. 4:32-34. 1995
- “An AVID Dissent”: Commentary. PACE - Pacing and Clinical Electrophysiology. 17:1712-1713. 1994
- Stroke Prevention in Atrial Fibrillation II Study.. The Lancet. 343:1509. 1994
- Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: An international multicenter study. Journal of the American College of Cardiology. 23:1521-1530. 1994
- Stroke Prevention in Atrial Fibrillation II Study. The Lancet. 343:1508-1509. 1994
- The impact of left ventricular dysfunction on outcomes with the implantable defibrillator. American Heart Journal. 127:1159-1163. 1994
- Role of antithrombotic therapy in atrial fibrillation.. Giornale Italiano di Cardiologia. 24:341-343. 1994
- Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): Rationale and protocol. American Journal of Cardiology. 72:F87-F94. 1993
- Canadian Implantable Defibrillator Study (CIDS): Study design and organization. American Journal of Cardiology. 72:F103-F108. 1993
- Development of residency program guidelines for interaction with the pharmaceutical industry. Education Council, Residency Training Programme in Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ont.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 149:405-408. 1993
- Standardized Reporting of ICD Patient Outcome: The Report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9–10, 1993. PACE - Pacing and Clinical Electrophysiology. 16:1358-1362. 1993
- Amiodarone for patients with ventricular premature depolarizations after myocardial infarction. Is it safe to stop treatment at one year?. Circulation. 87:637-639. 1993
- CLINICAL-TRIALS - TO TERMINATE OR NOT TO TERMINATE - REPLY. Annals of Internal Medicine. 116:700-700. 1992
- Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: The need for randomized trials. American Journal of Cardiology. 69:959-962. 1992
- Comparison of one-, six- and 24-hour ambulatory electrocardiographic monitoring for ventricular arrhythmia as a predictor of mortality in survivors of acute myocardial infarction. American Journal of Cardiology. 69:308-313. 1992
- Prevalence and predictors of ventricular premature complexes in survivors of acute myocardial infarction. American Journal of Cardiology. 69:408-411. 1992
- How Should Results from Completed Studies Influence Ongoing Clinical Trials?. ACP journal club. 115:818-822. 1991
- Stroke Prevention in Nonvalvular Atrial Fibrillation. ACP journal club. 115:727-736. 1991
- Canadian atrial fibrillation anticoaguiation (CAFA) study. Journal of the American College of Cardiology. 18:349-355. 1991
- Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy.. Circulation. 84:469-481. 1991
- Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study.. Circulation. 84:550-557. 1991
- The Diurnal Variability of Ventricular Premature Depolarizations: Influence of Heart Rate, Sleep, and Wakefulness. Sleep. 12:391-399. 1989
- Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. American Journal of Cardiology. 63:817-819. 1989
- Concentration response relationships of amiodarone and desethylamiodarone. American Heart Journal. 115:1208-1213. 1988
- Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. Journal of the American College of Cardiology. 10:1145-1148. 1987
- Diltiazem and Propranolol, Alone and in Combination, on Exercise Performance and Left Ventricular Function in Patients with Stable Effort Angina: A Double‐Blind, Randomized, and Placebo‐Controlled Study. Basic and Clinical Pharmacology and Toxicology. 57:55-60. 1985
- Liquid-chromatographic determination of amiodarone and its N-desethyl metabolite in plasma.. Clinical Chemistry. 30:1423-1424. 1984
- Propafenone disposition kinetics in cardiac arrhythmia. Clinical Pharmacology and Therapeutics. 36:163-168. 1984
- Pharmacodynamics of Intravenous Amiodarone in the Dog. Journal of Cardiovascular Pharmacology. 6:531-535. 1984
- Clinical efficacy and electrophysiology of imipramine for ventricular tachycardia. American Journal of Cardiology. 53:516-521. 1984
- CYCLICAL VARIATION OF THE HEART RATE IN SLEEP APNOEA SYNDROME. The Lancet. 323:126-131. 1984
- NEW ANTIARRHYTHMIC DRUGS - LOCAINIDE AND PROPAFENONE. Coeur; revue de cardiologie medico-chirurgicale. 15:357-366. 1984
- Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. American Journal of Cardiology. 52:1208-1213. 1983
- Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. American Journal of Cardiology. 52:490-494. 1983
- Clinical pharmacology of propafenone.. Circulation. 68:589-596. 1983
- The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study.. Circulation. 68:560-567. 1983
- Myocardial disposition of amiodarone in the dog.. Journal of Pharmacology and Experimental Therapeutics. 224:603-608. 1983